Company Overview of Polyphor Ltd
Polyphor Ltd. engages in the discovery and development of macro-cycle drugs. The company offers MacroFinder molecules, which penetrate into the cells to hit intracellular protein-protein interactions (PPI); and PEMfinder molecules that are used to address extracellular large surface PPI-targets. Its macro-cycles drugs target various therapeutic areas, such as hematopoietic stem cell transplantations, leukemia, pseudomonas infections, cystic fibrosis, alpha-1 antitrypsin deficiency, and chronic obstructive pulmonary diseases. The company was founded in 1996 and is headquartered in Allschwil, Switzerland.
Founded in 1996
Key Executives for Polyphor Ltd
Co-Founder and Chief Scientific Officer
Chief Financial Officer and Head of Coporate Development
Head of Technology Platforms
Compensation as of Fiscal Year 2015.
Polyphor Ltd Key Developments
Polyphor Ltd Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Polyphor Ltd Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Polyphor and Taisho Pharmaceutical Enter into Research Collaboration on Novel Drug Candidates
Sep 17 15
Polyphor Ltd. announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The parties will collaborate on the identification of novel drug candidates based on Polyphor's proprietary macrocycle platform.
Polyphor Ltd. Extends Clinical Development Portfolio by Advancing its inhaled Elastase Inhibitor POL6014 for Lung Diseases to Phase I
Sep 1 15
Polyphor Ltd. announced the initiation of recruitment in a first in man clinical Phase I study with inhaled POL6014, Polyphor's proprietary macrocycle drug candidate. POL6014 is a highly selective, potent and reversible inhibitor of human neutrophil elastase (hNE), which is implicated in a number of severe respiratory diseases that frequently lead to life-threatening progressive lung deterioration as, for instance, in the orphan lung diseases Alpha-1 Antitrypsin (AAT) Deficiency and Cystic Fibrosis (CF). Inhibition of excess hNE may stop or slow lung destruction and the progressive deterioration of lung function, characteristic of many obstructive lung diseases, resulting from the proteolytic (breakdown of proteins) activity of hNE in the lung. In addition, it may also help improve lung function, exacerbation profiles and overall quality of life of patients by reducing the pro-inflammatory effect of hNE in the lung. The randomized, double-blind, placebo-controlled dose-escalation Phase I study is designed to investigate safety, tolerability and pharmacokinetics of inhaled single doses of POL6014 in healthy volunteers. The study aims to establish a safe maximum tolerated dose for future clinical studies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries